Protagonist Therapeutics (PTGX) Profit After Tax (2015 - 2026)

Protagonist Therapeutics has disclosed Profit After Tax across 12 years of filings, most recently posting $3.8 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at $3.8 million, up 132.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$114.7 million (down 304.14% YoY), and the FY2025 annual result was -$130.1 million, down 147.29% from the prior year.
• Profit After Tax came in at $3.8 million for Q1 2026 at Protagonist Therapeutics, up from -$44.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $207.3 million in Q1 2024 to a low of -$44.4 million in Q4 2025.
• The 5-year median for Profit After Tax is -$33.2 million (2024), against an average of -$3.4 million.
• Across the five-year window, Profit After Tax jumped 714.8% in 2024 and slumped 133.71% in 2025, its largest moves.
• Protagonist Therapeutics' Profit After Tax stood at -$34.2 million in 2022, then soared by 179.94% to $27.3 million in 2023, then jumped by 381.7% to $131.7 million in 2024, then plunged by 133.71% to -$44.4 million in 2025, then soared by 108.52% to $3.8 million in 2026.
• The last three Profit After Tax figures came in at $3.8 million (Q1 2026), -$44.4 million (Q4 2025), and -$39.3 million (Q3 2025), per Business Quant data.